4bases
4bases SA is a Swiss CE-IVD NGS diagnostics company that develops and commercializes validated genetic reagent kits, bioinformatics software (4eVar), and diagnostic workflows for clinical laboratories and healthcare professionals across Europe.
- Company typePrivate
- Founded2013
- HeadquartersManno, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What 4bases does
4bases SA is a privately held Swiss biotechnology company, founded in 2013 and headquartered at Tecnopolo Ticino in Manno, Switzerland, with a production facility in Italy. The company develops, manufactures, and commercializes clinically validated, CE-IVD certified reagent kits, bioinformatics software, and diagnostic protocols for platform-independent Next Generation Sequencing (NGS). Its product portfolio spans targeted gene panels covering cardiovascular disease (CARDIO pro), hematologic malignancies (HEMATO pro, 146 genes), hereditary and somatic cancer predisposition (HEVA Pro), chronic kidney disorders (NEPHRO pro, 92 genes), thalassemia, familial hypercholesterolemia, BRCA1/2 analysis (BRaCA), clinical exome (ClinEX Pro), and whole exome sequencing (WholEx pro). The portfolio is complemented by the 4eVar cloud-based data analysis platform and the KaryoSolver workflow, which combines KaryoPrep library preparation with real-time software for copy number variant detection on nanopore sequencing devices, and InnoGraft, an RUO platform for non-invasive dd-cfDNA-based monitoring of solid organ transplant recipients.
The company's business model combines one-time sales of CE-IVD reagent kits with recurring subscription elements for cloud-based data analysis software (4eVar, KaryoSolver). It operates a sales-led go-to-market targeting clinical laboratories, hospital diagnostic centers, and healthcare professionals across Europe, with distribution via direct sales, regional distributors, and technology partnerships such as the collaboration with Oxford Nanopore Technologies and Meridian Bioscience. Customers include academic and public hospitals conducting pilot validations (Careggi University Hospital in Florence and a public hospital in Vicenza for KaryoSolver). Strategic priorities are evident in three partnerships executed within three years, most recently the June 2026 Meridian Bioscience agreement to lyophilize KaryoSolver for ambient-temperature global distribution, and product expansion into transplant medicine via InnoGraft. The company remains founder-controlled under CEO Fabio Grandi and has not disclosed external institutional funding rounds.
4bases firmographics
Firmographics- Name
- 4bases
- Legal name
- 4bases SA
- Website
- https://4bases.ch
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 4bases SA is a Swiss CE-IVD NGS diagnostics company that develops and commercializes validated genetic reagent kits, bioinformatics software (4eVar), and diagnostic workflows for clinical laboratories and healthcare professionals across Europe.
- Ownership category
- akta.pro rank
4bases industry classification
Industry- Product category
- Clinical Genetic Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where 4bases is headquartered
LocationHeadquarters
- HQ city
- Manno
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
4bases business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- CE-IVD Reagent Kits: Sale of clinically validated diagnostic reagent kits for platform-independent New Generation DNA Sequencing (NGS)
- Data Analysis Software: Software tools including 4eVar cloud platform and KaryoSolver software for genetic data analysis
- Diagnostic Kits: Commercialization of diagnostic kits including KaryoSolver for cytogenetics and InnoGraft for transplant monitoring
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
4bases product offering
Product offeringCore offering
4bases develops, produces, and commercializes CE-IVD certified diagnostic reagent kits for platform-independent Next Generation DNA Sequencing (NGS), alongside proprietary data analysis software and diagnostic protocols. Its portfolio includes targeted panels for cardiovascular, hematologic, oncologic, renal, and hereditary disease testing, as well as the KaryoSolver nanopore-based CNV detection workflow and the InnoGraft dd-cfDNA platform for transplant monitoring.
Product overview
4bases offers a comprehensive portfolio of CE-IVD genetic diagnostic solutions for Next Generation Sequencing (NGS), comprising capture-based reagent kits, bioinformatics software platforms, and diagnostic workflows. The product lineup includes: CARDIO pro (cardiovascular disease panel), HEMATO pro (hematologic malignancies panel covering 146 genes), HEVA Pro (hereditary cancer predisposition panel with 43+ genes), NEPHRO pro (chronic kidney disease panel with 92 genes), THALASSEMIA panel, BRaCA (BRCA1/2 analysis), ClinEX Pro, and WholEx pro (whole exome sequencing). Supporting platforms include 4eVar (cloud-based data analysis) and the KaryoSolver workflow (nanopore-based CNV detection). InnoGraft is the company's newest RUO product for transplant rejection monitoring via dd-cfDNA analysis. Products are designed for platform-independent NGS and include both CE-IVD certified diagnostic kits and Research Use Only products.
Differentiator
Problem solved
Functional benefit
Brands
- InnoGraft: Non-invasive platform for longitudinal monitoring of solid organ transplant recipients, detecting donor-derived cell-free DNA (dd-cfDNA) in recipient's plasma.
- KaryoSolver
- 4eVAR
- CARDIO pro
- HEVA pro
- WholEX pro
- NEPHRO pro
- HEMATO pro
- BRaCA
- ClinEX Pro
- THALASSEMIA panel
- FH panel
Products and services
- CARDIO pro CE-IVD capture-based diagnostic kit designed for the comprehensive genetic characterization of familial cardiovascular diseases. Identifies SNVs and CNVs in both somatic and germline samples. For clinical laboratories performing genetic cardiovascular testing.
- HEMATO pro CE-IVD kit for analysis of complex genomic variants associated with Lymphoid and Myeloid Diseases. Analyzes 146 genes frequently mutated in hematologic malignancies. Validated for germline and somatic analysis of SNVs, indels, CNVs and ITD.
- HEVA Pro Advanced targeted NGS capture panel for comprehensive analysis of genes associated with hereditary and somatic cancer predisposition. Includes all ESMO-recommended core genes plus 43 additional genes involved in hereditary cancer susceptibility.
- NEPHRO pro CE-IVD panel for the analysis of 92 genes associated with hereditary kidney disorders, including Chronic Kidney Disease.
- THALASSEMIA panel NGS medical device for molecular profiling of variants causing alpha and beta Thalassemia. Analyzes HBB, HBA1, HBA2, HBD, HBG1, HBG2, HS-40 and LCRB genes. Validated for germline analysis of SNPs and indels from blood samples.
- FH panel Diagnostic solution for assessment of Familial Hypercholesterolemia. Includes LDLR, APOB, and PCSK9 genes plus 6 other genes associated with FH.
- BRaCA CE-IVD kit for analysis of BRCA1 and BRCA2 genes. Compatible with Oxford Nanopore Technologies devices. Demonstrated 100% concordance with gold-standard methods (short-read sequencing, MLPA, Sanger sequencing) in internal studies.
- ClinEX Pro CE-IVD panel compatible with Oxford Nanopore Technologies for comprehensive genetic profiling in genetically heterogeneous disorders.
- WholEx pro Whole exome sequencing kit with coverage of over 99% of protein-coding genes, enabling identification of various pathologies including rare diseases.
- InnoGraft Non-invasive platform for longitudinal monitoring of solid organ transplant recipients. Detects donor-derived cell-free DNA (dd-cfDNA) in recipient plasma using a proprietary panel of 94 highly polymorphic SNPs. Features AI-driven cloud analytics for rejection risk evaluation, delivering results within 24 hours. Protected by two patents.
- KaryoSolver Real-time workflow for copy number variant (CNV) detection based on nanopore sequencing. Consists of KaryoPrep library preparation and KaryoSolver software for real-time data analysis via the 4eVar cloud platform. Targets prenatal diagnostics and oncohematology applications.
- 4eVar Proprietary cloud-based platform for real-time data analysis. Performs bioinformatics analysis for variant detection and copy number variant (CNV) analysis in NGS workflows.
- Microbiology Kits NGS kits for microbial genomics analysis, including integration with One Codex for end-to-end microbiome analysis solutions in the EU.
Quantifiable outcome
- KaryoSolver achieved 100% detection of known pathogenic/likely pathogenic variants in clinical validation study (509 samples)
- +3 more outcomes
Companies that use 4bases
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
4bases technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature4 records
4bases partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and strategic.
- Meridian BiosciencecoreCollaboration focused on expanding global access to KaryoSolver through Meridian's advanced lyophilization expertise. Meridian enabled ambient-stable NGS workflows by stabilizing the library preparation components, eliminating cold-chain requirements and extending shelf life for simplified global distribution. The partnership combines 4bases' assay design with Meridian's reagent stabilization platform.
- PlatomicsstrategicStrategic agreement with Platomics GmbH to facilitate laboratory regulatory documentation under EU In Vitro Diagnostic Regulation (IVDR). The PlatoX platform streamlines generation of documentation for laboratory workflows through automation, templates, and integrated guidance, helping 4bases customers navigate regulatory compliance.
- Oxford Nanopore TechnologiescoreStrategic collaboration to combine nanopore sequencing devices with 4bases kits for rapid, high-accuracy analyses in human and cancer genetics. Initial focus on same-day BRCA1 and BRCA2 analysis with 100% concordance to gold-standard methods. Enables decentralized, flexible sequencing scalability for clinical researchers in Italy and Switzerland.
- Alberto Magi (University of Florence)coreCollaboration with Professor Alberto Magi (Professor of Bioengineering, University of Florence) on KaryoSolver development and pilot studies in Italian hospitals. Prof. Magi leads validation studies at Careggi University Hospital (Florence) and public hospital system in Vicenza, generating clinical evidence on reproducibility, turnaround time, and resolution.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
4bases competitors and assessment
Company assessmentEmerging players
- TATAA Biocenter: Sweden-based molecular diagnostics provider offering qPCR/NGS services and reagents for clinical and research applications. Comparable European molecular diagnostics focus with overlapping customer base, though smaller product portfolio than 4bases.
Direct peers
- Devyser: Swedish company developing CE-IVD diagnostic kits for hereditary diseases using NGS. Closest direct comparable — similar size, similar product focus on hereditary/cardiovascular/cancer panels, and similar platform-independent NGS strategy targeting clinical labs in Europe.
- Nonacus: UK-based developer of NGS library preparation and target enrichment reagents for clinical and research applications. Comparable in product category (NGS library prep/capture kits), size, and clinical lab customer focus.
- NimaGen: Dutch molecular diagnostics company producing CE-IVD NGS reagent kits and library preparation solutions for hereditary and oncology applications. Similar scale, product mix (CE-IVD kits + bioinformatics), and European clinical lab customer base.
- CareDx: US-based transplant diagnostics company commercializing donor-derived cell-free DNA (dd-cfDNA) tests such as AlloSure for graft rejection monitoring. Direct comparable for InnoGraft's transplant monitoring value proposition, though much larger and commercially established.
- Asuragen: US-based molecular diagnostics company developing CE-IVD and LDT-grade NGS kits for oncology and genetic disease applications. Comparable in product mix (CE-IVD NGS kits), regulatory strategy, and clinical lab customer focus.
Broad incumbents
- SOPHiA Genetics: Swiss-founded health technology company offering a broader cloud-based genomics platform for molecular diagnostics across hereditary cancers, rare diseases, and oncology. Overlaps with 4bases on NGS-based diagnostic workflows but operates a software/data analytics business model at significantly larger scale.
- Agilent Technologies (Resolution Bioscience / Multiplicom): Major life sciences tools company with a dedicated molecular diagnostics division including NGS kits for hereditary disease (formerly Multiplicom, acquired 2016). Comparable product category and CE-IVD positioning but operates at vastly larger scale with broader portfolio.
- Eurofins Genoma / Eurofins Transplant Genomics: Eurofins division offering molecular and transplant diagnostics services including dd-cfDNA testing. Competes with InnoGraft in transplant monitoring while Eurofins' broader portfolio overlaps with 4bases' clinical lab offerings at much larger scale.
Others
- Oxford Nanopore Technologies: Sequencing platform partner and adjacent ecosystem participant. While not a direct competitor (they sell sequencers, 4bases sells kits), their expanding menu of clinical IVD assays and partnerships with other kit developers positions them as both an enabler and a potential competitive threat to 4bases' nanopore-based workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
4bases social profiles
Digital presence4bases compliance and trust
Trust signalCompliance2 records
4bases financial estimates
Financial estimateRevenue estimate
Valuation estimate
4bases leadership team
Management profileNumber of profiles
Profiles1 record
4bases funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
4bases M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 4bases
What does 4bases do?
4bases develops, produces, and commercializes CE-IVD certified diagnostic reagent kits for platform-independent Next Generation DNA Sequencing (NGS), alongside proprietary data analysis software and diagnostic protocols. Its portfolio includes targeted panels for cardiovascular, hematologic, oncologic, renal, and hereditary disease testing, as well as the KaryoSolver nanopore-based CNV detection workflow and the InnoGraft dd-cfDNA platform for transplant monitoring.
Is 4bases a public or private company?
4bases is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 4bases founded?
4bases was founded in 2013. It employs 1 to 10 people.
Where is 4bases based?
4bases is headquartered in Manno, Switzerland, in the Europe region.
How does 4bases make money?
Three revenue lines are on record. CE-IVD Reagent Kits are the primary driver. The others are data Analysis Software and diagnostic Kits.
Who are 4bases's main competitors?
TATAA Biocenter is listed as an emerging player. Direct peers are Devyser, Nonacus, NimaGen, CareDx and Asuragen. Broad incumbents are SOPHiA Genetics, Agilent Technologies (Resolution Bioscience / Multiplicom) and Eurofins Genoma / Eurofins Transplant Genomics. Oxford Nanopore Technologies is listed as an others.
Does 4bases have an API?
No public API is recorded for 4bases.
What industry is 4bases in?
4bases's product category is Clinical Genetic Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.